Long-term NAD+ supplementation prevents the progression of age-related hearing loss in mice.
Ontology highlight
ABSTRACT: Age-related hearing loss (ARHL) is the most common sensory disability associated with human aging. Yet, there are no approved measures for preventing or treating this debilitating condition. With its slow progression, continuous and safe approaches are critical for ARHL treatment. Nicotinamide Riboside (NR), a NAD+ precursor, is well tolerated even for long-term use and is already shown effective in various disease models including Alzheimer's and Parkinson's disease. It has also been beneficial against noise-induced hearing loss and in hearing loss associated with premature aging. However, its beneficial impact on ARHL is not known. Using two different wild-type mouse strains, we show that long-term NR administration prevents the progression of ARHL. Through transcriptomic and biochemical
SUBMITTER: Okur MN
PROVIDER: S-EPMC10497810 | biostudies-literature | 2023 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA